Search
Displaying 321–330 of 1144 results
-
SparingVision Recruiting for Clinical Trial of Cone-Preserving Gene Therapy for RP
Research NewsFirst cohort of patients has been dosed in Phase ½ clinical trial taking place in Pittsburgh and Paris
-
Atsena Doses First Patient in XLRS Gene Therapy Clinical Trial
Research NewsThe AAV.SPR gene delivery system used in the trial is designed to more safely reach targeted retinal cells
-
FDA Approves 8 MG Dosing of Eylea for Wet AMD, Diabetic Macular Edema, and Diabetic Retinopathy
Research NewsNew, higher treatment dose reduces frequency of eye injections for patients
-
Life as a Teen with Retinitis Pigmentosa
Beacon StoriesAt a mere 15 years old, Ava Ruggiero’s world shifted when she received a diagnosis of retinitis pigmentosa. As Ava continues to find balance as a student and athlete, she discusses the challenges of navigating her diagnosis alongside her parents, Joseph and Stephanie.
-
Eye on the Cure Podcast | Episode 51: Artur Cideciyan, PhD
Eye on the CureAugust 18, 2023. Artur Cideciyan, PhD, one of the world’s foremost authorities in measuring vision and structural changes in people with retinal diseases, talks with host Ben Shaberman about current imaging tools, functional tests, and his experience as an investigator in several prominent clinical trials at the University of Pennsylvania, Scheie Eye Institute.
-
June 21–June 22, 2024. Chicago Marriott Downtown Magnificent Mile, Chicago, Illinois. VISIONS 2024, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, hear about exciting advancements in blindness research.
-
Talented Singer Overcomes Blindness with the Power of Melodies
Beacon StoriesSarah Hardwig’s love for music began from her earliest days, creating a purpose that would sustain even in the face of adversity. Diagnosed with Leber congenital amaurosis (LCA) before her first birthday, the young artist continues to defy all odds and utilize her voice as a powerful beacon of hope.
-
IZERVAY Approved by FDA for Treatment of Geographic Atrophy Secondary to Advanced Dry AMD
Research NewsIn two Phase 3 clinical trials, IZERVAY slowed the growth rate of lesions, the regions of cell loss in the central retina, associated with geographic atrophy (GA)
-
Karen Petrou Appointed Foundation Chair Effective July 1, 2024, Upon the Retirement of David Brint
Foundation NewsSpecial Foundation Announcement from Jason Menzo
-
Belite Bio Doses First Patient in Phase 3 Clinical Trial for Advanced Dry AMD (GA) Therapy
Research NewsThe company’s emerging, oral treatment is designed to slow vision loss
.png)
%20(10).png)
.jpg)
